Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Exlinkibart by Lyvgen Biopharma for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC). According to...
Exlinkibart by Lyvgen Biopharma for Advanced Malignancy: Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase I for Advanced Malignancy. According to GlobalData, Phase...
Exlinkibart by Lyvgen Biopharma for Soft Tissue Sarcoma: Likelihood of Approval
Exlinkibart is under clinical development by Lyvgen Biopharma and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData,...